期刊文献+

治疗癌症的新途径:靶向肿瘤微环境 被引量:16

A novel cancer therapeutic strategy:targeting tumor microenvironment
下载PDF
导出
摘要 传统的癌症治疗方法是以直接杀死肿瘤细胞为基础,近年来靶向肿瘤微环境成为治疗肿瘤的新途径。肿瘤微环境主要通过诱导新生血管形成、抑制免疫监视和免疫反应、孕育肿瘤干细胞等促进肿瘤发生及转移。理论上靶向肿瘤微环境的肿瘤治疗应有高效、低毒、广谱的特点。限于对肿瘤微环境的了解,目前以肿瘤微环境为靶成功治疗肿瘤的例子并不多。本文就肿瘤微环境对肿瘤的调控、靶向肿瘤微环境治疗肿瘤的现状、存在的问题及发展趋势进行综述。 Conventional cancer therapies are based on killing tumor cell directly.Recently,targeting tumor microenviron-ment becomes a novel approach for cancer treatment.The tumor microenvironment may promote tumor formation and metastasis mainly via angiogenesis induction,suppression of immune surveillance and immune response,and breeding tumor stem cells.Targeting therapy at tumor microenvironment theoretically has several characters,such as strong effect,low toxicity and broad anti-tumor spectrum.However,there are few succeedful precedents in tumor treatment targeting tumor microenvironment.In this paper,we summarize the regulation effect of tumor microenvironment on the pathogenesis of tumor,present status,problems and developments trendency of targeting tumor microenvironment.
出处 《国际药学研究杂志》 CAS 2011年第5期336-340,共5页 Journal of International Pharmaceutical Research
基金 河南大学省部共建项目(SBGJ090704) 河南省青年骨干教师项目(2010GGJS-025) 河南省科技厅重点科技攻关项目(112101310308) 国家自然科学基金项目(81173094)
关键词 肿瘤微环境 血管形成 免疫逃逸 化疗抵抗 血管正常化 tumor microenvironment angiogenesis immune escape chemoresistance vessel normalization
  • 相关文献

参考文献1

二级参考文献39

  • 1Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction [J]. Clin Cancer Res, 2003,9(6): 1957-1971.
  • 2Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome [J]. Cancer Metastasis Rev, 2007,26(2):225-239.
  • 3Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases [J]. Nature, 2000,407(6801):249-257.
  • 4Mendoza E, Burd R, Wachsberger P, et at. Normalization of tumor vasculature and improvement of radiation response by antiangiogenic agents [M]. Humana Press Inc, 2008:311-321.
  • 5Jain RK, Duda DG, Clark JW, et al. Lessons from phase Ill clinical trials on anti-VEGF therapy for cancer [J]. Nat Clin Pract Oncot, 2006,3(1 ):24-40.
  • 6Greenberg JI, Shields D J, Baritlas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation [J]. Nature, 2008,456(7223):809 813.
  • 7Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fiuorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004,350(23):2335-2342.
  • 8Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a muttidisciplinary phase Ⅱ study [J]. J Clin Oncol, 2009,27(18):3020-3026.
  • 9Sun Y, Wang J, Liu Y, et al. Results of phase III trial of rhendostatin (YH-16) in advanced non-small ceil lung cancer (NSCLC) patients [J]. J Clin Oncol, 2005,23(16):654S.
  • 10Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action [J]. Exp Cell Res, 2006,312(5):594-607.

共引文献4

同被引文献312

引证文献16

二级引证文献217

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部